Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $53
Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Pricing Concerns
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
USA pharmaceutical stocks 'switching trading': two weight-loss giants fall, while stagnant giants rise in turn.
The rotation of this stock price is not only due to momentum effects, but also because the USA pharmaceutical industry seems to have responded well to the regulatory pressure brought by the Inflation Reduction Act.
Bristol-Myers Squibb Options Spot-On: On July 29th, 84,323 Contracts Were Traded, With 861.54K Open Interest
Barclays Cuts Bristol Myers to Underweight, Cites Recent Run up
103189865 : mony half widrow
103159190 : Why is McDonald's earnings forecast lower than expected and the pre-market price will rise?
104371487 On Paris : Thanks you
105535782 : ok
Captain Woon 103159190 : Market is irrational… buy on bad news
View more comments...